Völzke Henry, Ittermann Till, Schmidt Carsten O, Dörr Marcus, John Ulrich, Wallaschofski Henri, Stricker Bruno H C, Felix Stephan B, Rettig Rainer
SHIP/Clinical-Epidemiological Research Unit, Institute of Community Medicine, Ernst Moritz Arndt University of Greifswald, Walther Rathenau Strasse 48, D-17487 Greifswald, Germany.
Eur J Endocrinol. 2009 Oct;161(4):615-21. doi: 10.1530/EJE-09-0376. Epub 2009 Jul 6.
There is current controversy on the association between subclinical hyperthyroidism and hypertension. Data from cohort studies have not been available yet. The present study was designed to longitudinally investigate possible associations of subclinical hyperthyroidism with blood pressure, pulse pressure and the risk of hypertension.
We used data from the population-based, prospective cohort Study of Health in Pomerania and included 2910 subjects (1469 women) aged 20-79 years with completed 5-year examination follow-up. Subjects with increased serum TSH levels or overt hyperthyroidism were excluded. Serum TSH levels below 0.25 mIU/l with free triiodothyronine and free thyroxine levels within the reference range were defined as subclinical hyperthyroidism. Blood pressure was measured according to standard methods.
Multivariable analyses adjusted for age, sex, overweight, obesity, smoking status and time between the examinations did not reveal any statistically significant association between subclinical hyperthyroidism and any of the blood pressure-related variables in the whole study population. Although the 5-year hypertension incidence was higher in subjects with subclinical hyperthyroidism compared with those without (31.4 vs 19.2%; risk ratio 1.64; 95% confidence interval (CI) 1.17-2.28, P=0.006), both groups did not differ with respect to the risk of hypertension, after analyses were adjusted for confounders (relative risk 1.23, 95% CI 0.91-1.68, P=0.182). Analyses yielded similar results in subjects without thyroid disease and in those who took no antihypertensive medication.
Subclinical hyperthyroidism is not associated with changes in blood pressure, pulse pressure or incident hypertension.
目前关于亚临床甲状腺功能亢进与高血压之间的关联存在争议。队列研究的数据尚未可得。本研究旨在纵向调查亚临床甲状腺功能亢进与血压、脉压及高血压风险之间的可能关联。
我们使用了基于人群的前瞻性波美拉尼亚健康队列研究的数据,纳入了2910名年龄在20 - 79岁之间且完成了5年检查随访的受试者(1469名女性)。排除血清促甲状腺激素(TSH)水平升高或显性甲状腺功能亢进的受试者。血清TSH水平低于0.25 mIU/l且游离三碘甲状腺原氨酸和游离甲状腺素水平在参考范围内被定义为亚临床甲状腺功能亢进。血压按照标准方法测量。
在对年龄、性别、超重、肥胖、吸烟状况和两次检查之间的时间进行调整的多变量分析中,未发现亚临床甲状腺功能亢进与整个研究人群中任何血压相关变量之间存在统计学上的显著关联。尽管亚临床甲状腺功能亢进患者的5年高血压发病率高于无亚临床甲状腺功能亢进者(31.4%对19.2%;风险比1.64;95%置信区间(CI)1.17 - 2.28,P = 0.006),但在对混杂因素进行调整后,两组在高血压风险方面并无差异(相对风险1.23,95% CI 0.91 - 1.68,P = 0.182)。在无甲状腺疾病的受试者和未服用抗高血压药物的受试者中,分析得出了相似的结果。
亚临床甲状腺功能亢进与血压、脉压变化或高血压发病无关。